BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

LTKfarma Pursues Development Of Proprietary TK Therapy


1/8/2010 1:30:49 PM

Evry, France – January 8, 2010 LTKfarma announces that in the patent litigation initiated against Molmed S.p.A. by Université Pierre et Marie Curie (UPMC) and LTKfarma on June 8, 2007, and based on the Italian part of European patent EP 0 564 646, the Court of Milan ruled on October 21, 2009, that the plaintiffs had the standing to bring the suit. Because of lack of sufficient evidence of an imminent marketing of the TK therapy by Molmed, the Court rejected UPMC and LTKfarma’s claims.

Nevertheless, considering the claims of UPMC and LTKfarma legitimate in substance, the Court rejected Molmed’s counterclaim for awarding “punitive” damages.

In conclusion, the Italian part of European patent EP 0 564 646 remains in force.

UPMC and LTKfarma will pursue their efforts for a proper respect of their rights on proprietary TK therapy.

About LTKfarma

LTKfarma is a biotechnology company founded in 2006 and located at the Genopole of Evry (France). The company is based on 20 years of research in immunology and on the clinical use of suicide genes, notably the thymidine kinase gene (TK). The company is dedicated to the development of new cell therapies products to improve allogeneic hematopoietic cells transplantation by providing, through TK Therapy, a mean of controlling Graft vs Host Disease (GvHD), a severe immune reaction that occurs following transplantation. The TK therapy has been validated in several clinical trials. Allogeneic hematopoietic cell transplantation is currently used to treat various blood cancers after relapse following standard chemotherapy. The security given by LTK products will allow to improve the current performances of the procedure and to extend its usage not only in the treatment of blood cancer, but also in other pathologies such as severe forms of auto-immune diseases or solid tumors.

For more information please go to: www.ltkfarma.com


Read at BioSpace.com

LTKfarma
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES